Second, to further clarify the regulatory role of SMIT1 in the AKT pathway, in vivo experiments—such as a combined treatment group (e.g., AKT agonist plus SMIT1 knockdown) in the tumor xenograft model—would help verify whether SMIT1 exerts its effects in an AKT-dependent manner. Here, AKT1 is linked to neoplasm.